+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 14 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating the effectiveness, safety, and tolerability of combining adagrasib with pembrolizumab and platinum-based chemotherapy compared to a placebo combined with pembrolizumab and platinum-based chemotherapy. This study includes participants with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC who have a KRAS G12C mutation. It is a phase 3, randomized, double-blind trial sponsored by Mirati Therapeutics Inc. Participants will receive either adagrasib plus pembrolizumab plus platinum-doublet chemotherapy or placebo plus pembrolizumab plus platinum-doublet chemotherapy. The chemotherapy agents include carboplatin, pemetrexed, or cisplatin, administered at specified doses on specified days. The study uses a parallel assignment model with quadruple masking. The treatment phase involves these medications, with ongoing monitoring for up to seven years to assess progression-free survival and overall survival. During the trial, participants will undergo regular imaging scans such as CT or MRI to measure disease response according to RECIST v1.1 criteria. Researchers will track outcomes including tumor progression, overall response, duration of response, safety events like adverse and serious adverse events, and quality of life using questionnaires. Safety monitoring continues up to 90 days after the last dose. The total study period may last up to seven years to collect long-term survival and symptom data.

Age: 18Years +All GendersPhase 3
317 locations
S

Actively Recruiting

Researchers are evaluating whether adding sacituzumab tirumotecan to pembrolizumab after surgery improves treatment outcomes for adults with resectable non-small cell lung cancer NSCLC who did not achieve a complete response after initial therapy. The study focuses on comparing disease-free survival between participants receiving pembrolizumab alone and those receiving a combination of pembrolizumab and sacituzumab tirumotecan. The trial is a phase 3, randomized, open-label study sponsored by Merck Sharp & Dohme LLC. Participants first receive pembrolizumab combined with platinum-based doublet chemotherapy as neoadjuvant therapy before surgery. After surgery, participants who did not achieve pathological complete response are assigned to one of two groups one group receives sacituzumab tirumotecan every two weeks for up to 12 doses alongside pembrolizumab every six weeks for up to seven cycles, while the other group receives pembrolizumab monotherapy every six weeks for up to seven cycles. The neoadjuvant chemotherapy includes drugs such as cisplatin, pemetrexed, gemcitabine, carboplatin, and paclitaxel, chosen based on tumor histology. Throughout the study, participants will be monitored regularly with assessments including imaging scans to evaluate disease status and quality of life questionnaires. The primary outcome is disease-free survival assessed by blinded independent central review for up to approximately 93 months. Secondary outcomes include overall survival, lung cancer-specific survival, adverse events, and changes in physical functioning and symptoms related to lung cancer. The study duration can last up to nearly 10 years with follow-up visits to monitor health and treatment effects.

Age: 18Years +All GendersPhase 3
270 locations
P

Actively Recruiting

Researchers are comparing the effects of two treatment combinations in adults with stage IV or recurrent non-squamous non-small cell lung cancer NSCLC that has a PD-L1 expression of 1% or higher. This phase 3 trial investigates whether Nivolumab and Relatlimab combined with chemotherapy works differently than Pembrolizumab with chemotherapy as first-line treatment for this condition. The study is sponsored by Bristol-Myers Squibb and uses a randomized parallel design. Participants will be assigned to one of two groups one group receives Nivolumab and Relatlimab with chemotherapy drugs, while the other group receives Pembrolizumab with chemotherapy. Chemotherapy may include drugs such as Carboplatin, Pemetrexed, or Cisplatin, given at specified doses on specific days. Treatment schedules and doses are carefully planned, and participants are treated during the trial period. During the study, participants undergo regular assessments to measure overall survival, progression-free survival, response rates, and duration of response, with follow-up lasting up to five years. Researchers also track adverse events and immune-related side effects for up to 2.5 years. Quality of life is monitored through symptom questionnaires. Assessments include imaging scans and laboratory tests to evaluate disease status and treatment effects. The total duration of participation may extend over several years to capture long-term outcomes and safety.

Age: 18Years +All GendersPhase 3
329 locations
R

Actively Recruiting

Researchers are investigating treatments for participants with unresectable stage III Non-small Cell Lung Cancer NSCLC who have completed platinum-based concurrent chemoradiation therapy without disease progression. This Phase 3 randomized study compares the effects of two drugs, Pumitamig and Durvalumab, to evaluate their impact on progression-free survival and other clinical outcomes over several years. The trial is sponsored by Bristol-Myers Squibb and aims to better understand treatment options after initial chemoradiation. Participants are randomly assigned to receive either Pumitamig or Durvalumab monotherapy, each given at specified doses on specified days. The study treatment follows completion of concurrent chemoradiotherapy, with no masking or placebo involved. The trial includes an observation period lasting up to three years for primary outcome measures and extends up to approximately nine years for overall survival monitoring. During the study, participants will undergo regular assessments to monitor progression-free survival based on standardized imaging criteria, along with evaluations of overall survival, response rates, disease control, and treatment duration. These assessments are conducted by blinded independent reviewers and investigators. Participants will be monitored closely for safety and treatment effects throughout the trial, which spans several years from enrollment through long-term follow-up.

Age: 18Years +All GendersPhase 3
260 locations
P

Actively Recruiting

This research aims to evaluate the effectiveness of AZD5335 compared to standard treatments in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. The study focuses on whether AZD5335 improves progression-free survival PFS among participants with either high or low levels of folate receptor alpha FR. Approximately 1100 adult women will be enrolled and divided into two groups based on their FR levels. Participants will be randomized within each group to receive either AZD5335 or the relevant standard treatment. Those with high FR levels will receive AZD5335 or mirvetuximab soravtansine, while those with low FR levels will receive AZD5335 or a chemotherapy agent chosen by the investigator, including paclitaxel, pegylated liposomal doxorubicin, or topotecan. Treatments are given intravenously, and participants will continue treatment until disease progression or other reasons for stopping. During the study, participants will undergo regular tumor assessments to monitor disease status. Researchers will follow all participants over time to evaluate overall survival. Safety and efficacy data will be reviewed periodically by an independent committee. The primary outcome is progression-free survival, measured for up to about five years. The study completion is expected by late 2029.

Age: 18Years +FEMALEPhase 3
299 locations
S

Actively Recruiting

Researchers are evaluating the effect of continued nutritional support after hospital discharge compared to usual care in medical patients at nutritional risk. This trial focuses on adults who have experienced malnutrition, a condition linked to higher risks of death, rehospitalization, and loss of function, especially among elderly and multi-ill patients. Previous studies showed that in-hospital nutritional support helps reduce complications and mortality, but the long-term benefits after discharge remain unclear. Participants are randomly assigned to one of two groups. The intervention group receives customized nutritional support from an experienced dietician to meet their individual energy and protein needs, including oral nutritional supplements as needed. The control group receives general advice on healthy eating habits at discharge without ongoing nutritional support. Follow-up includes regular phone calls every 2 to 4 weeks to monitor adherence and adjust dietary plans as necessary. During the study, participants are monitored for up to three years. Researchers assess key outcomes such as time to death from any cause, hospital readmissions, major complications, and changes in functional status using the Barthel index. Quality of life is measured with the European Quality of Life 5 Dimensions index and a visual-analogue scale at regular intervals by phone. This comprehensive follow-up helps determine whether sustained nutritional support after discharge improves long-term health and recovery.

Age: 18Years +All GendersPhase Not Applicable
18 locations
M

Actively Recruiting

Researchers are evaluating the addition of letrozole, an aromatase inhibitor, to the standard maintenance therapy in women diagnosed with estrogen-receptor ER positive epithelial ovarian cancer, including fallopian tube and primary peritoneal cancer. This study focuses on both low and high grade serous or endometrioid ovarian cancers at FIGO Stage II-IV, whose cancer has not progressed after primary surgery and platinum-based chemotherapy. The main goal is to determine if letrozole can increase progression-free survival compared to the current standard maintenance treatment with placebo. Participants are randomly assigned to receive either letrozole 2.5 mg daily or a placebo tablet once daily for up to five years or until toxicity symptoms or disease progression occur. This randomized, double-blinded, multicenter phase III trial involves 540 eligible women who will be monitored throughout the treatment period. The study also includes a sub-study focusing on low grade ovarian cancer LOGOS. Treatment adherence and tolerability will be assessed during regular visits. Participants will undergo health assessments including blood tests, physical and gynecological exams, and possibly imaging during routine follow-ups every 12 weeks for the first two years, then every 24 weeks for three additional years. Quality of life will be evaluated using specific questionnaires, and participants will wear an activity tracker for one week before visits. Researchers will measure progression-free survival as the primary outcome and also evaluate overall survival, time to next treatment, and quality-adjusted survival. Follow-up data will be collected for up to 12 years, including up to seven years after treatment ends to monitor long-term outcomes.

Age: 18Years +FEMALEPhase 3
53 locations
C

Actively Recruiting

Researchers are evaluating how the timing of immune checkpoint inhibitor ICI therapy affects treatment outcomes in people with advanced melanoma. The study focuses on whether giving these therapies earlier in the day, aligned with the bodys natural immune rhythms, can improve effectiveness, especially in female patients. This prospective, randomized trial aims to clarify the complex relationship between sex, circadian immune function, and response to ICIs. Participants will be randomly assigned to receive standard-of-care ICI treatments during either an early morning window 800 to 1200 or a late afternoon window 1500 to 1800. The treatments include drugs such as nivolumab, pembrolizumab, and the combination of ipilimumab with nivolumab, given intravenously on schedules typical for each medication. Treatment phases include induction and maintenance cycles depending on the therapy used, with dosing intervals ranging from every 2 to 4 weeks. During the study, participants will be monitored from the time of randomization up to six years to assess progression-free survival, overall survival, and objective response rate. Researchers will conduct regular clinical assessments and follow participants closely to evaluate treatment effects and safety. The trial emphasizes personalized timing of treatment to potentially enhance immune response without additional costs or toxicity.

Age: 18Years +All GendersPhase 2
9 locations
F

Actively Recruiting

Researchers are evaluating the feasibility and potential effects of a nurse-led physical activity program called OncoMoveNurse for people with cancer receiving outpatient care. The study focuses on improving physical activity behavior, self-efficacy, well-being, and mood during systemic cancer treatment. This mixed-methods study is conducted in an oncology day clinic setting and aims to understand how nurses can promote an activity-friendly culture to help patients stay active despite treatment challenges. The OncoMoveNurse program consists of five key components a modular exercise catalogue, safety protocols, communication strategies, team collaboration, and person-centered care. Supporting materials such as posters, videos, and exercise tools have been developed. The study spans 15 months, including preparation, implementation, and evaluation phases. Nurses lead the implementation with training and feedback sessions, and the program is integrated into routine outpatient care. Data collection includes patient-reported outcome measures and qualitative methods like digital storytelling and focus groups involving patients and healthcare professionals. Participants will be engaged during their outpatient visits where they receive support from oncology nurses to increase physical activity safely. Researchers will collect quantitative data on physical activity levels, self-efficacy, and quality of life, alongside qualitative feedback. All data are anonymized and analyzed to assess program feasibility and effects. The study runs from October 2024 through December 2025, with patient data collected mainly between June and September 2025. This research aims to inform future physical activity promotion in oncology outpatient care.

Age: 18Years +All Genders
1 location
G

Actively Recruiting

Researchers are conducting a Phase 23, multisite, randomized, open-label trial to study first-line treatments for non-small cell lung cancer NSCLC. This trial includes two substudies focusing on different NSCLC histological subtypes due to variations in standard chemotherapy choices. The study aims to evaluate the safety, effectiveness, and behavior of the investigational drug pumitamig combined with chemotherapy and compare it to pembrolizumab plus chemotherapy. Participants in each substudy first join a Phase 2 part where they receive one of two doses of pumitamig plus chemotherapy. In the Phase 3 part, they are randomized to receive either pumitamig plus chemotherapy or pembrolizumab plus chemotherapy. Additional participants in China will be enrolled in a Phase 2 arm to further evaluate a selected dose. Independent committees will review safety data and tumor scans throughout the study. Participants will be involved for up to 64 months, undergoing treatments through intravenous infusions. Their health will be monitored regularly to track side effects, tumor response, progression-free survival, overall survival, and quality of life through questionnaires and scans. Safety assessments include monitoring adverse events and treatment tolerance, with follow-up visits extending up to several years to assess long-term outcomes.

Age: 18Years +All GendersPhase 2Phase 3
366 locations

1-10 of 14

1